Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria?

Abstract

Incomplete systemic lupus (iSLE) is an acknowledged condition of patients with clinical signs of lupus who do not fulfill classification criteria for SLE. Some patients with iSLE have persistent mild disease, but others have serious organ involvement, and up to 55% progress to established SLE. Research on this subject could reveal predictive or diagnostic biomarkers for SLE. Ideally, it would become possible to discern those patients with critical organ involvement or a high risk for progression to SLE. This high‐risk group might benefit from early treatment, which would preferably be confirmed in randomized controlled trials. This process would, however, require agreement on a definition of iSLE. The Systemic Lupus International Collaborating Clinics (SLICC) classification criteria was composed in order to diagnose SLE earlier. The present review outlines the clinical characteristics of iSLE after introduction of SLICC criteria and furthermore proposes a definition of iSLE with the aim of discriminating the high‐risk group from those with a lower risk.

A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus

“…Because family history has been recently included in the definition of incomplete lupus as a risk factor for the development of SLE (10), we evaluated the family history of the patients with pSLE included in our study. We found no association of family history of autoimmune rheumatic diseases (SLE, rheumatoid arthritis, psoriatic arthritis, or Sjogren syndrome; n = 30) or family history of SLE only (n = 19) (Table 4) with the transition to classifiable SLE ( P = 0.470 and P = 0.785, respectively).…”

Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic

“…Фигурируют такие дефиниции, как «ранняя» (early lupus), «потенциальная» (potential lu pus), «неполная» (incomplete lupus), «вероятная» или «преклиническая» (preclinical lupus) СКВ и, наконец, «СКВ неуточненная» (МКБ 10). В ревматологии в настоящее время наиболее часто используется определение «неполная» СКВ [29][30][31][32]. Инт ерес к проблеме «неполной» СКВ связан со многими факторами, имеющими как практическое (улучшение ранней диагностики), так и теоретическое значение, связанное с расшифровкой «тригенных» этиологических факторов и «ранних» механизмов потери иммунологической толерантности к собственным антигенам.…”

A Combination of Complement Activation Products With Autoantibodies Predicts Transition of Probable Lupus to Systemic Lupus Erythematosus: Comment on the Article by Lambers et al

“…We read with interest the review by Lambers at al recently published in Arthritis Care & Research (1), and we welcome the authors' attempt to provide a definition of incomplete systemic lupus erythematosus (SLE) and a summary of possible clinical and laboratory predictors of transition to SLE.…”

“…We welcome the attempt to develop a diagnostic test that can predict progression to SLE. Early identification of SLE is one of the main challenges faced by clinicians and is hindered by both the heterogeneous presenting symptoms of the disease, as well as overlap with other diseases (1,2). Timely treatment, however, is important in order to limit disease progression and prevent organ damage and mortality (3).…”